

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-24. (canceled)

2 25. (currently amended) The conjugate of Claim 1 ~~38~~ wherein in the PEG molecule is covalently attached to the hinge region of the antibody fragment.

26-28. (canceled)

3 29. (currently amended) The conjugate of Claim 28 ~~38~~ wherein the anti-human IL-8 said antigen binding site comprises the complementarity determining region regions of a light chain polypeptide amino acid sequence selected from the group consisting of the 6G4V11N35A light chain polypeptide amino acid sequence of Fig. 36 (SEQ ID NO: 56) and the 6G4V11N35E light chain polypeptide amino acid sequence of Fig. 45 (SEQ ID NO: 62).

30. (canceled)

14 31. (currently amended) A composition comprising the conjugate of Claim 1 ~~38~~ and a carrier.

15 32. (original) The composition of Claim 31 that is sterile.

4 38. (currently amended) The conjugate of Claim 1 ~~38~~, wherein the covalent structure of the conjugate is free of any matter other than the antibody fragment and nonproteinaceous polymer PEG molecules that form the conjugate.

5 34. (currently amended) The conjugate of Claim 1 ~~38~~, wherein the covalent structure of the conjugate incorporates one or more nonproteinaceous labels, and

wherein the covalent structure of the conjugate is free of any matter other than the antibody fragment, ~~nonproteinaceous polymer~~ PEG and nonproteinaceous label molecules that form the conjugate.

~~6~~ <sup>5</sup> 35. (original) The conjugate of Claim ~~34~~ wherein at least one nonproteinaceous label is radiolabel.

~~7~~ <sup>6</sup> 36. (currently amended) A conjugate comprising a humanized antibody Fab' fragment,

wherein said antibody fragment: (a) binds to human interleukin 8 (IL-8); (b) comprises the complementarity determining regions of (i) 6G4V11N35A light chain (Fig. 36, SEQ ID NO: 56) or (ii) 6G4V11N35E light chain (Fig. 45, SEQ ID NO: 62), and (c) is covalently attached to a single polyethylene glycol (PEG) molecule of at least 20 kD, and

wherein said conjugate has an apparent size of at least about 500 kD and at least about 8 fold greater than the apparent size of the antibody fragment.

~~8~~ <sup>7</sup> 37. (currently amended) A conjugate comprising ~~an~~ a humanized antibody Fab' fragment,

wherein said antibody fragment: (a) binds to human interleukin 8 (IL-8); (b) comprises the complementarity determining regions of (i) 6G4V11N35A light chain (Fig. 36, SEQ ID NO: 56) or (ii) 6G4V11N35E light chain (Fig. 45, SEQ ID NO: 62), and (c) is covalently attached to a polyethylene glycol (PEG) molecule having an average molecular weight of at least about 40 kD,

wherein the apparent size of the conjugate is at least about 500 kD, and at least about 8 fold greater than the apparent size of the antibody fragment.

38. (currently amended) A conjugate comprising a humanized antibody Fab' fragment further comprising an antigen binding site,

wherein said antigen binding site (a) that binds to human interleukin-8 (IL-8), and (b) wherein the anti-human IL-8 antigen binding site comprises the complementarity determining region regions of a light chain polypeptide amino acid sequence selected from the group consisting of: (i) the 6G4V11N35A light chain polypeptide amino acid sequence of (Fig. 36, (SEQ ID NO: 56) and or (ii) the 6G4V11N35E light chain polypeptide amino acid sequence of (Fig. 45, (SEQ ID NO: 62),

wherein said humanized antibody Fab' antibody fragment being is covalently attached to a polyethylene glycol (PEG) molecule having an average molecular weight of at least 20 kD, and

wherein the apparent size of the conjugate is at least about 500 kD, and at least about 8 fold greater than the apparent size of the antibody fragment.

9 39. (currently amended) A composition comprising the conjugate of Claim 37 ~~29~~ and a carrier.

10 40. (withdrawn) The composition of Claim 39 that is sterile.

11 41. (Previously presented) A composition comprising the conjugate of Claim 38 and a carrier.

12 42. (Previously presented) The composition of Claim 41 that is sterile.

13 43. (New) The conjugate of Claim 38 wherein said antigen binding site comprises the complementarity determining regions of Fig. 45 (SEQ ID NO: 62).